MOLECULAR AND CHEMICAL DESCRIPTION OF CFTR FUNCTION
CFTR 功能的分子和化学描述
基本信息
- 批准号:2143431
- 负责人:
- 金额:$ 16.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1991
- 资助国家:美国
- 起止时间:1991-05-01 至 1996-08-31
- 项目状态:已结题
- 来源:
- 关键词:adenosine triphosphate antibody binding proteins cell membrane chemical binding chlorine circular dichroism cystic fibrosis fluorescence spectrometry gene deletion mutation genetic manipulation hydrolysis molecular cloning molecular pathology nuclear magnetic resonance spectroscopy peptide chemical synthesis phenylalanine phosphorylation protein kinase protein kinase C protein purification protein structure function proteins
项目摘要
The objectives of this proposal are to complete some very straightforward
studies which should greatly facilitate our understanding of both the
molecular and chemical basis of cystic fibrosis (CF). The proposed studies
will focus on the CFTR protein (cystic fibrosis transmembrane conductance
regulator), predicted from cDNA sequence analysis to be 1480 amino acids
In length. The predicted protein Includes both a large membrane spanning
region and a large cytoplasmic domain, the latter consisting of two
putative ATP binding regions (ATP-1, and ATP-11) and a putative regulatory
region (R) thought to be a protein kinase target. Significantly, almost
70% of CF patients lack a phenylalanine in the center of the ATP-1 region.
Consequently, it has been suggested that the wild type CFTR may be an 'ion
motive' ATPase which couples ATP hydrolysis to Cl- transport, and that the
phenylalanine deletion mutation may alter the binding or hydrolysis of ATP
and, therefore, Cl- transport. With these thoughts in mind, the Specific
Aims of this proposal are sixfold:
1.Prepare In large amounts, using both chemical and molecular biological
approaches, the two cytoplasmic regions, ATP-1 and ATP-11, of the 'wild
type" CFTR protein.
2.Characterize the resultant peptides physically, and assess their capacity
to bind and hydrolyze ATP In the presence and absence of Cl-.
3.Prepare as in '1' the ATP-1 region containing the single phenylalanine
deletion found in most cystic fibrosis patients.
4.Characterize physically the ATP-1 phenylalanine mutant peptide and assess
its capacity to bind and hydrolyze ATP in the presence and absence of Cl-.
5.Prepare, as in "l", a "wild type' and a phenylalanine mutant peptide
containing both the regulatory region 'R' and the ATP-1 region, and compare
these peptides' capacity to bind and hydrolyze ATP before and after
treatment with protein kinases A or C.
6.Assess the effect of antibodies to the ATP-1, ATP-11, and R + ATP-1
regions on the ATPase activity of epithelial cell membranes.
The proposed studies are fundamental for understanding the molecular and
chemical basis of cystic fibrosis, and may encourage future experiments
directed at replacing only a small portion of the "wild type" CFTR gene in
CF patients.
这项建议的目的是完成一些非常简单的
这些研究将极大地促进我们对
囊性纤维化(CF)的分子和化学基础。 拟议的研究
将重点关注CFTR蛋白(囊性纤维化跨膜传导
调节子),从cDNA序列分析预测为1480个氨基酸
长的 预测的蛋白质包括一个大的跨膜
区域和一个大的胞质结构域,后者由两个
假定的ATP结合区(ATP-1和ATP-11)和假定的调节区(ATP-11)。
区域(R)被认为是蛋白激酶靶标。 重要的是,几乎
70%的CF患者在ATP-1区域的中心缺乏苯丙氨酸。
因此,已经表明野生型CFTR可能是一种“离子”,
动力性ATP酶,它将ATP水解与Cl-转运偶联,
苯丙氨酸缺失突变可改变ATP的结合或水解
以及氯离子的运输。 带着这些想法,具体
该提案的目标有六个方面:
1.大量制备,使用化学和分子生物学
采用这种方法,“野生型”的两个细胞质区域ATP-1和ATP-11
CFTR蛋白。
2.对所得肽进行物理表征并评估其能力
在Cl-存在和不存在的情况下结合并水解ATP。
3.如“1”中所述制备含有单个苯丙氨酸的ATP-1区域
在大多数囊性纤维化患者中发现缺失。
4.物理表征ATP-1苯丙氨酸突变肽并评估
在Cl-存在和不存在的情况下结合和水解ATP的能力。
5.如“1”中所示,制备“野生型”和苯丙氨酸突变体肽
含有调节区“R”和ATP-1区,并比较
这些肽在前后结合和水解ATP的能力
用蛋白激酶A或C处理。
6.评估抗体对ATP-1、ATP-11和R + ATP-1的影响
上皮细胞膜上ATP酶活性的区域。
所提出的研究是理解分子和
囊性纤维化的化学基础,并可能鼓励未来的实验
目的是仅替换一小部分“野生型”CFTR基因,
CF患者
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER L PEDERSEN其他文献
PETER L PEDERSEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER L PEDERSEN', 18)}}的其他基金
FASEB SUMMER RESEARCH CONFERENCE: TRANSPORT ATPASES
FASEB 夏季研究会议:运输ATP酶
- 批准号:
6359997 - 财政年份:2001
- 资助金额:
$ 16.15万 - 项目类别:
FASEB SUMMER RESEARCH CONFERENCE--TRANSPORT ATPASES
FASEB夏季研究会议--运输ATP酶
- 批准号:
2881784 - 财政年份:1999
- 资助金额:
$ 16.15万 - 项目类别:
Cancer-Related Glycolytic Gene:Regulation and Targeting
癌症相关糖酵解基因:调控和靶向
- 批准号:
7228866 - 财政年份:1998
- 资助金额:
$ 16.15万 - 项目类别:
相似海外基金
Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
- 批准号:
502607 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
- 批准号:
EP/Y024540/1 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Fellowship
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
- 批准号:
MR/Y008847/1 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
- 批准号:
BB/Y002180/1 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Research Grant
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
- 批准号:
MR/Y003616/1 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
- 批准号:
MR/Y033698/1 - 财政年份:2024
- 资助金额:
$ 16.15万 - 项目类别:
Research Grant
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
- 批准号:
23H03716 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Analysis research of anti-Sez6l2 antibody associated encephalopathy
抗Sez6l2抗体相关脑病的分析研究
- 批准号:
23K06940 - 财政年份:2023
- 资助金额:
$ 16.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)